ITEM 5 – OTHER INFORMATION
−Removed: During the quarter ended September 30, 2024, no
−Removed: director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is
−Removed: defined in Item 408(a) of Regulation S-K.
+Added: During the quarter ended March 31, 2025, no director
+Added: or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in
+Added: Item 408(a) of Regulation S-K.
ITEM 6 – EXHIBITS
2 unchanged sentences
EXHIBIT NUMBER
+Added: Consulting Agreement, dated January 1, 2025, between Xenetic Biosciences, Inc.
+Added: and Dmitry Genkin (incorporated by reference to Exhibit 10.31 filed with the Company’s Annual Report on Form 10-K on March 18, 2025).
Certification of James Parslow, Interim Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of James Parslow, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of James Parslow, Interim Principal Executive Officer and Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in inline XBRL, include:
−Removed: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements.
+Added: Certifications of James Parslow, Interim Principal Executive Officer and Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in inline XBRL, include:
+Added: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements.
Cover Page Interactive Data File (formatted in inline XBRL and included in Exhibit 101).
5 unchanged sentences
Xenetic Biosciences, Inc.
−Removed: November 12, 2024
/s/ JAMES PARSLOW
1 unchanged sentence
Interim Chief Executive Officer and Chief Financial Officer
−Removed: (Principal Executive, Principal Financial Officer and Principal Accounting Officer)
+Added: (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.